Seattle Genetics Presents Data From SGN-35 Program

June 10, 2005

Seattle Genetics has presented data from its SGN-35 development program at the 9th International Conference on Malignant Lymphoma in Lugano, Switzerland.

SGN-35 is an antibody-drug conjugate (ADC) composed of an anti-CD30 monoclonal antibody stably linked to a highly potent auristatin derivative using Seattle Genetics' second generation ADC technology. The company plans to initiate clinical trials of SGN-35 in early 2006, initially for the treatment of CD30-positive malignancies, including Hodgkin's disease.

In preclinical models of anaplastic large cell lymphoma, SGN-35 displays a dose-dependent antitumor effect, including complete regressions at repeat doses as low as 0.5 mg/kg and one mg/kg given as a single dose. The efficacious doses are well below the maximum-tolerated dose and pharmacokinetic analyses demonstrate that the ADC has a prolonged half-life in circulation.